Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- GSK Investigational Site
-
-
Colorado
-
Wheat Ridge, Colorado, United States, 80033
- GSK Investigational Site
-
-
Maine
-
Biddeford, Maine, United States, 04005
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- GSK Investigational Site
-
-
New Jersey
-
Summit, New Jersey, United States, 07091
- GSK Investigational Site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, United States, 16508
- GSK Investigational Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- GSK Investigational Site
-
Spartanburg, South Carolina, United States, 29303
- GSK Investigational Site
-
-
Tennessee
-
Johnson City, Tennessee, United States, 37601
- GSK Investigational Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Washington
-
Spokane, Washington, United States, 99204
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male and females 40 to 80 years of age (inclusive)
- COPD diagnosis
- Current or previous smokers with a cigarette smoking history of at least 10 pack-
- Post-albuterol FEV1/FVC of 0.70 or less
- Post-albuterol FEV1 of 35% to 80% (inclusive)
Exclusion Criteria:
- Pregnant or lactating females
- current diagnosis of asthma
- respiratory disorders other than COPD
- clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine, or hematological abnormalities that are uncontrolled
- clinically significant sleep apnea
- previous lung resection surgery
- clinically significant abnormalities confirmed by chest x-ray that are not related to COPD
- hospitalization for COPD within 3 months of screening
- use of antibiotics for lower respiratory tract infection within 6 months of screening
- abnormal and clinically significant 12-lead ECG findings
- current malignancy in remission for less that 5 years
- medical conditions that would contraindicate the use of anticholinergics
- positive hepatitis B or C test
- history of alcohol or drug abuse
- unable to withhold albuterol for 6 or more hours
- use of long term oxygen therapy
- conditions that would limit the validity of informed consent
- use of GW642444 or GSK233705 in previous studies
- use of an investigation drug with 30 days of screening
- use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone propionate or equivalent
- hypersensitivity to beta-agonists
- concurrent use of long-acting beta-agonists (LABA) or long-acting muscaring antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators, inhaled short acting anticholinergics.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
|
The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
|
|
Placebo Comparator: Arm 2
|
matching placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Weighted Mean Pulse Rate Over (0-4 Hours) at Day 28.
Time Frame: Baseline (Pre-dose, Day 1) and Day 28
|
Baseline was the most recent result taken on or before pre-dose (Day 1).
The analysis was performed using a Repeated Measures Model.
This model used all available weighted mean pulse rate values recorded.
Change from Baseline was calculated as (Change from Baseline = Assessment value - Baseline value).
|
Baseline (Pre-dose, Day 1) and Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: On-treatment; from treatment start until one day after treatment stop (Up to Day 29)
|
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.
Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
|
On-treatment; from treatment start until one day after treatment stop (Up to Day 29)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DB1111581
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Study Protocol
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: DB1111581Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.